CYP2C9&z.ast;3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics

Pharmazie

Volumn 68, Issue 3, 2013, Pages 187-194

  Zhou, Quan ^a   Chen, Qiu Xia ^a   Ruan, Zou Rong ^a   Yuan, Hong ^a   Xu, Hui Min ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; SEX DIFFERENCE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DNA; FEMALE; GENOTYPE; HALF-LIFE; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES; REPRODUCIBILITY OF RESULTS; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84874851195     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.2742     Document Type: Article

References (26)

1. Choi CI, Lee YJ, Lee HI, Kim BH, Kim MJ, Jang CG, Bae JW, Lee SY (2012) Effects of the SLCO1B1&z.ast;15 allele on the pharmacokinetics of pitavastatin. Xenobiotica 42: 496-501.
2. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ (2005) Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78: 342-350.
3. Fujino H, Saito T, Ogawa S, Kojima J (2005) Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 57: 1305-1311.
4. Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDPglucuronosyltransferase enzymes involved in lactonization. Xenobiotica 33: 27-41.
5. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M (2002) Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 52: 745-753.
6. GuoY, ZhangY,WangY, Chen X, Si D, Zhong D, Fawcett JP, ZhouH(2005) Role of CYP2C9 and its variants (CYP2C9&z.ast;3 and CYP2C9&z.ast;13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33: 749-753.
7. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin (2005) Mol Pharmacol 68: 800-807.
8. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1&z.ast;5, SLCO1B1&z.ast;15 and SLCO1B1&z.ast;15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15: 513-522.
9. Kim SR, Saito Y, Sai K, Kurose K, Maekawa K, Kaniwa N, Ozawa S, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Saijo N, Sawada J (2007) Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1&z.ast;17 is more prevalent than &z.ast;15. Drug Metab Pharmacokinet 22: 456-461.
10. Kivistö KT, Niemi M (2007) Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 24: 239-247.
11. Kivistö KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype &z.ast;17. Pharmacogenet Genomics 5: 303-309.
12. Morita N, Yasumori T, Nakayama K (2003) Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65: 1843-1852.
13. Mukhtar RY, Reid J, Reckless JP (2005) Pitavastatin. Int J Clin Pract 59: 239-252.
14. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75: 415-421.
15. Niemi M, Pasanen MK, Neuvonen PJ (2006) SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80: 356-366.
16. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype &z.ast;17. Pharmacogenet Genomics 15: 303-309.
17. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429-440.
18. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I (2011) Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J Pharm Sci 100: 3843-3453.
19. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72: 572-583.
20. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10: 95-104.
21. Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 276: 35669-35675.
22. Vormfelde SV, Toliat MR, Schirmer M, Meineke I, Nürnberg P, Brockmöller J (2008) The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele &z.ast;3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 83: 815-817.
23. Wen J, Xiong Y (2010) OATP1B1 388A >G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 35: 99-104.
24. Xiang Q, Cui YM, Zhao X, Yan L, Zhou Y (2012) The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers. Pharmacology 89: 105-110.
25. Xu LY, He YJ, Zhang W, Deng S, Li Q, Zhang WX, Liu ZQ, Wang D, Huang YF, Zhou HH, Sun ZQ (2007) Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol Sin 28: 1693-1697.
26. Yang GP, Yuan H, Tang B, Zhang W, Wang LS, Huang ZJ, Ou-Yang DS, Zhang GX, Zhou HH (2010) Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients. Acta Pharmacol Sin 31: 382-386.